Source comparison
CJC-1295 no DAC vs DAC: Research Application Comparison
Before selecting a peptide for your research protocol, understanding the practical and mechanistic distinctions between CJC-1295 no DAC (Modified GRF 1-29) and CJC-1295 with DAC is essential. The table below compares key research variables to guide evidence-ba
This comparison does not assign a generated winner or score.
- Before selecting a peptide for your research protocol, understanding the practical and mechanistic distinctions between CJC-1295 no DAC (Modified GRF 1-29) and CJC-1295 with DAC is essential. The table below compares key research variables to guide evidence-based peptide selection.
- Plasma Half-Life
- ~30 minutes
- 6–8 days
- No DAC variant mimics endogenous GHRH kinetics; DAC extends duration but sacrifices physiological fidelity
- Growth Hormone Release Pattern
- Pulsatile (discrete pulses 2–3 hours post-dose)
- Sustained elevation over days
- Pulsatile patterns required for studies examining ultradian rhythm or receptor dynamics
- Dosing Frequency
- 1–3 times daily
- Once weekly
- Frequency aligns with research objective. Pulsatile studies require multi-dose; chronic exposure studies use weekly
- Receptor Desensitization Risk
- Low (clears between doses, allows receptor recycling)
- Moderate to high (continuous occupancy promotes downregulation)
- Extended protocols favor no DAC to preserve response amplitude
- Synergy with Growth Hormone Secretagogues
- High (precise timing of dual-pathway stimulation)
- Limited (constant background GHRH signal reduces synergistic clarity)
- Co-administration studies require pulsatile GHRH analog for interpretable data
- Washout Period for Crossover Studies
- 6–8 hours to baseline
- 4–6 weeks
- No DAC enables rapid protocol iteration; DAC requires extended washout